Current Perspectives on HIV-1 Antiretroviral Drug Resistance

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2014 Oct 25

PMID 25341668

Citations 68

Authors

Pinar Iyidogan

Karen S Anderson

Affiliations

Soon will be listed here.

Abstract

Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly.

Citing Articles

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.

Apetroaei M, Velescu B, Nedea M, Dinu-Pirvu C, Draganescu D, Faca A Biomedicines. 2024; 12(4).

PMID: 38672269 PMC: 11048092. DOI: 10.3390/biomedicines12040915.

Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase.

Prucha G, Henry S, Hollander K, Carter Z, Spasov K, Jorgensen W Eur J Med Chem. 2023; 262:115894.

PMID: 37883896 PMC: 10872499. DOI: 10.1016/j.ejmech.2023.115894.

Shared molecular signatures between coronavirus infection and neurodegenerative diseases provide targets for broad-spectrum drug development.

Deng L, Ding L, Duan X, Peng Y Sci Rep. 2023; 13(1):5457.

PMID: 37015947 PMC: 10071237. DOI: 10.1038/s41598-023-29778-4.

Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase.

Carter Z, Hollander K, Spasov K, Anderson K, Jorgensen W Bioorg Med Chem Lett. 2023; 84:129216.

PMID: 36871704 PMC: 10278203. DOI: 10.1016/j.bmcl.2023.129216.

Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study.

Zhou Z, Meng B, An J, Zhao F, Sun Y, Zeng D Int J Mol Sci. 2023; 24(2).

PMID: 36674730 PMC: 9865928. DOI: 10.3390/ijms24021215.

References

Anastassopoulou C, Ketas T, Klasse P, Moore J . Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A. 2009; 106(13):5318-23. PMC: 2664029. DOI: 10.1073/pnas.0811713106. View

Hanna G, Johnson V, Kuritzkes D, Richman D, Brown A, Savara A . Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis. 2000; 181(3):904-11. DOI: 10.1086/315329. View

Bretscher M, Althaus C, Muller V, Bonhoeffer S . Recombination in HIV and the evolution of drug resistance: for better or for worse?. Bioessays. 2004; 26(2):180-8. DOI: 10.1002/bies.10386. View

Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D . TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005; 79(20):12773-82. PMC: 1235844. DOI: 10.1128/JVI.79.20.12773-12782.2005. View

Boyer P, Sarafianos S, Arnold E, Hughes S . Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol. 2002; 76(18):9143-51. PMC: 136461. DOI: 10.1128/jvi.76.18.9143-9151.2002. View

Rouzine I, Brunet E, Wilke C . The traveling-wave approach to asexual evolution: Muller's ratchet and speed of adaptation. Theor Popul Biol. 2007; 73(1):24-46. PMC: 2246079. DOI: 10.1016/j.tpb.2007.10.004. View

Larder B, Coates K, Kemp S . Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol. 1991; 65(10):5232-6. PMC: 249001. DOI: 10.1128/JVI.65.10.5232-5236.1991. View

Rimsky L, Shugars D, Matthews T . Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998; 72(2):986-93. PMC: 124569. DOI: 10.1128/JVI.72.2.986-993.1998. View

Miller M, Margot N, Lu B, Zhong L, Chen S, Cheng A . Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004; 189(5):837-46. DOI: 10.1086/381784. View

10.

Grande-Perez A, Lazaro E, Lowenstein P, Domingo E, Manrubia S . Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A. 2005; 102(12):4448-52. PMC: 555496. DOI: 10.1073/pnas.0408871102. View

11.

Canducci F, Sampaolo M, Marinozzi M, Boeri E, Spagnuolo V, Galli A . Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009; 23(4):455-60. DOI: 10.1097/QAD.0b013e328323da60. View

12.

Ray A, Murakami E, Peterson C, Shi J, Schinazi R, Anderson K . Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Res. 2002; 56(3):189-205. DOI: 10.1016/s0166-3542(02)00102-x. View

13.

Deval J, Alvarez K, Selmi B, Bermond M, Boretto J, Guerreiro C . Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs. J Biol Chem. 2004; 280(5):3838-46. DOI: 10.1074/jbc.M411559200. View

14.

Sheehy A, Gaddis N, Choi J, Malim M . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646-50. DOI: 10.1038/nature00939. View

15.

Preston B, Poiesz B, Loeb L . Fidelity of HIV-1 reverse transcriptase. Science. 1988; 242(4882):1168-71. DOI: 10.1126/science.2460924. View

16.

Ren J, Milton J, Weaver K, Short S, Stuart D, Stammers D . Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure. 2000; 8(10):1089-94. DOI: 10.1016/s0969-2126(00)00513-x. View

17.

Hizi A, TABONE J, Solomon M, Loeb L . Inefficient repair of RNA x DNA hybrids. Eur J Biochem. 1998; 250(2):492-501. DOI: 10.1111/j.1432-1033.1997.0492a.x. View

18.

Malim M, Emerman M . HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe. 2008; 3(6):388-98. DOI: 10.1016/j.chom.2008.04.008. View

19.

Harris R, Bishop K, Sheehy A, Craig H, Petersen-Mahrt S, Watt I . DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113(6):803-9. DOI: 10.1016/s0092-8674(03)00423-9. View

20.

Mansky L, Temin H . Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995; 69(8):5087-94. PMC: 189326. DOI: 10.1128/JVI.69.8.5087-5094.1995. View